Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 113 results for "Vivitrol"

Alkermes raises full year forecasts as it prepares new drug launch
Irish Times

Alkermes raises full year forecasts as it prepares new drug la...

Company gears up for new schizophrenia drug Aristada as opioid/alcohol therapy Vivitrol beats expectations Alkermes president Shane Cooke. Photograph: Kate Geraghty/ The Irish Times Dominic Coyle Topics: Business Pharma & MedTech Shane Cooke Fda ... Irish Times, 5 days ago

28 images for Vivitrol

Fix.com, 1 month ago
Fix.com, 1 month ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago
Raleigh News & Observer, 3 months ago

The Bergand Group, Maryland's Leading Addiction Recovery Partners, Now...

The Bergand Group, with offices in Towson and Bel Air, Maryland, now offers Vivitrol as a medication management option to help reduce opioid and alcohol dependence during treatment. Medication Management at The Bergand Group is always used in ...
 PRWeb1 month ago

Alkermes Posts 2Q 2015 Financial Results

Alkermes reported financial results for the second quarter of 2015. "With the PDUFA date for ARISTADA, our proposed brand name for aripiprazole lauroxil, just a few weeks away, we are in the midst of final launch preparations for this important ...
 4 Traders1 day ago Alkermes Plc (ALKS) Releases Quarterly Earnings Results  WKRB News4 days ago ALKERMES PLC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations  Pharmacy Choice5 days ago Alkermes' (ALKS) CEO Richard Pops on Q2 2015 Results - Earnings Call Transcript  Seeking Alpha5 days ago
[x]  

Medication and Treatment for Substance Abuse from Renaissance Ranch Outpatient Treatment

Renaissance Ranch Outpatient Treatment offers a unique approach to substance abuse treatment. They integrate medically proven methods with a gospel-centered approach to help patients recover. The programs aim to provide a physical, emotional, ...
 Press Release Ping1 day ago Substance Abuse Treatment Market Segment Forecasts up to 2020, Research Reports- TransparencyMarketResearch  ARN3 weeks ago Substance Abuse Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2020  Digital Journal2 months ago
[x]  

Brokerages Set Alkermes Plc PT at $67.33 (NASDAQ:ALKS)

Shares of Alkermes Plc (NASDAQ:ALKS) have earned a consensus recommendation of Hold from the fourteen analysts that are currently covering the stock, Analyst Ratings Net reports . Four equities research analysts have rated the stock with a sell ...
 WKRB News5 days ago Brokerages Set Alkermes Plc Target Price at $67.33 (NASDAQ:ALKS)  SleekMoney2 days ago Alkermes Plc Price Target Raised to $48.00 at Goldman Sachs (ALKS)  SleekMoney2 weeks ago Alkermes Plc Receives $69.75 Consensus Target Price from Brokerages (NASDAQ:ALKS)  SleekMoney1 month ago

Alkermes Plc's Buy Rating Reiterated at JPMorgan Chase & Co. (ALKS)

JPMorgan Chase & Co. reaffirmed their buy rating on shares of Alkermes Plc (NASDAQ:ALKS) in a report published onThursday, AnalystRatingsNetwork.com reports. They currently have a $77.00 target price on the stock. In other Alkermes Plc news, COO ...
 WKRB News2 days ago Alkermes Plc Stock Rating Reaffirmed by JPMorgan Chase & Co. (ALKS)  SleekMoney3 days ago Alkermes Plc Given Buy Rating at Cowen and Company (ALKS)  WKRB News5 days ago

Alkermes Plc Downgraded to Sell at Zacks (ALKS)

Zacks reduced shares of Alkermes Plc (NASDAQ:ALKS) from a hold rating to a sell evaluation in a research note released on Friday morning, AnalystRatingsNetwork.com reports. According to Zacks, Alkermes reported more extensive than anticipated ...
 SleekMoney3 days ago Alkermes Plc Downgraded by Zacks to Sell (ALKS)  SleekMoney2 weeks ago Alkermes Plc Lowered to Sell at Zacks (ALKS)  SleekMoney2 weeks ago

Alkermes' Reports Wider Q2 Loss, Increases Guidance

Alkermes ( ALKS - Analyst Report ) reported a loss (including share-based compensation expense) of 24 cents per share in the second quarter of 2015 wider than the Zacks Consensus Estimate of a loss of 22 cents and the loss of 1 cent in the year ...
 Zacks.com4 days ago
[x]  
Examiner.com

New state budget supports substance abuse and addiction treatment

Our state officials are putting their money where their mouths are and building a budget with substantial new funding for treatment of substance use and addictions. The current budget, which will most likely be signed into effect by Governor Charlie ...
 Examiner.com1 week ago State Budget Includes Provision Blocking State Funds for Olympics  Boston Magazine3 weeks ago

Shane Cooke Sold $1,256,225 Worth of Alkermes Plc (NASDAQ:ALKS) Stock

Shane Cooke Insider Sell Transaction An insider of the company Alkermes Plc (NASDAQ:ALKS) 67.83 -1.17 -1.70% , Shane Cooke also its President Alkermes plc, disclosed his trading activities with the U.S. SEC on July 24, 2015. As shown in the ...
 Octafinance1 week ago Insider Selling: Alkermes Plc CFO Sells 20,000 Shares of Stock (ALKS)  SleekMoney2 weeks ago Insider Selling: Robert A. Breyer Sells 2,000 Shares of Alkermes Plc Stock (ALKS)  SleekMoney1 month ago Insider Selling: Alkermes Plc insider Sells $1,203,120.00 in Stock (ALKS)  SleekMoney1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less